13:46 , Jan 16, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies identified a naphthalenone-based Hsp90 inhibitor that could help treat glioblastoma. Screening of a small molecule library in a HeLa cell-based activity assay, followed by optimization and in...
17:24 , Aug 17, 2018 |  BC Week In Review  |  Company News

Glaukos, D. Western partner for glaucoma therapies

Glaukos Corp. (NYSE:GKOS) partnered with D. Western Therapeutics Institute Inc. (Tokyo:4576) to explore combining compounds from D. Western's rho-associated coiled-coil containing protein kinase (ROCK) library with Glaukos' iDose drug delivery system to treat glaucoma. Glaukos...
07:00 , Apr 11, 2016 |  BC Week In Review  |  Clinical News

WP-1303: Phase I started

D. Western began a Japanese Phase I trial to evaluate single and multiple doses of WP-1303 in healthy volunteers. The start of the trial triggered an undisclosed milestone payment to D. Western from Wakamoto under...
07:00 , Sep 29, 2014 |  BC Week In Review  |  Clinical News

K-134: Phase II ongoing

D. Western said it is "probably difficult to proceed" with a planned Phase III trial of K-134 after the compound missed the primary endpoint in the double-blind, placebo-controlled, dose-finding portion of a Japanese Phase II...
07:00 , Jul 1, 2013 |  BioCentury  |  Finance

2Q Stock Wrap-Up: If it ain't broke

Despite one segment that finished the second quarter in the red, all market cap groups are still up for the year. In 2Q13, the sector was led by large caps, which closed up 4%, marking...
07:00 , May 20, 2013 |  BC Week In Review  |  Company News

D. Western, Wakamoto Pharmaceutical deal

In March, D. Western granted Wakamoto exclusive rights in Japan to H-1129 , which is in development to treat glaucoma and ocular hypertension. D. Western received ¥50 million ($530,000) up front and is eligible for...
07:00 , Mar 21, 2013 |  BC Innovations  |  Targets & Mechanisms

Understanding fibrosis

Researchers at The University of Alabama at Birmingham have identified idiopathic pulmonary fibrosis as a repurposing opportunity for fasudil, a Rho kinase inhibitor that Asahi Kasei Pharma Corp. markets as Eril to treat aneurysm. The...
08:00 , Feb 11, 2013 |  BioCentury  |  Finance

Bubbling up in Japan

Japan's biotech stocks have benefited from a spike in interest from retail investors driven in part by last October's Nobel Prize for a Kyoto University stem cell researcher. Company executives who spoke with BioCentury are...
07:00 , Aug 13, 2012 |  BC Week In Review  |  Company News

D. Western, Kowa deal

D. Western received ¥75 million ($960,000) in the second tranche of a milestone payment from Kowa triggered by the start of Japanese Phase IIb trials of K-134 . D. Western received ¥37 million ($473,600) in...
07:00 , Jul 18, 2011 |  BioCentury  |  Finance

RaQualia scores

RaQualia scores In one of the largest biotech IPOs ever in Japan, RaQualia Pharma Inc. last week raised ¥6.4 billion ($79.4 million), giving it a post-money valuation of ¥21.5 billion ($266.6 million) and putting its...